Ors had a greater percentage of DDR mutations than type I tumors (70.59 vs. 28.85

Ors had a greater percentage of DDR mutations than type I tumors (70.59 vs. 28.85 , p 0.001, chi-squared test). The advancedBiomedicines 2021, 9,9 ofstage individuals had larger percentage of DDR mutations than the early-stage individuals (57.28 vs. 27.54 , p 0.001, chi-squared test). Recurring sufferers had a higher percentage of DDR mutations than those without having recurrence (53.92 vs. 32.86 , p = 0.006, chi-squared test). Patients who died of EOC had a greater percentage of DDR mutations than living patients (59.21 vs. 34.38 , p = 0.001, chi-squared test). EOC individuals without having DDR gene mutation had longer progression-free survival (PFS) (p = 0.0072, log-rank test, Figure 2A) and general survival (OS) (p = 0.022, log-rank test, Figure 2B) than these with 1 DDR or two DDR mutations. In serous carcinoma, patients with or without having DDR mutations had comparable PFS (p = 0.56, log-rank test, Figure 2C). Individuals with 2 DDR mutations had a trend of improved OS than these with 1 mutation or none, however it was not statistically significant (p = 0.47, log-rank test, Figure 2D). In DBCO-Maleimide Protocol endometrioid carcinoma, patients with two DDR gene mutations had shorter PFS (p = 0.0035, log-rank test, Figure 2E) and OS (p = 0.015, log-rank test, Figure 2F) than these with 1 mutation or none. In clear cell carcinoma, individuals with 2 DDR gene mutations had significantly shorter PFS (p = 0.0056, log-rank test, Figure 2G) and OS (p = 0.0046, log-rank test, Figure 2H) than those with 1 DDR mutation or none. Tumor recurrence with CCR gene mutation (HR: 1.68 (1.12.50), p = 0.011), 1 DDR gene mutation (HR: 1.71 (1.12.60), p = 0.013), endometrioid Methylene blue custom synthesis carcinoma (HR: 0.17 (0.08.37), p 0.001), type II tumor (HR: 2.69 (1.81.00), p 0.001), advanced-stage carcinoma (HR: five.29 (3.16.85), p 0.001), high-grade tumor (HR: 5.57 (two.263.70), p 0.001) and optimal debulking surgery (HR: 0.28 (0.18.41), p 0.001) were significant in the univariate Cox regression model (Table 5). Advanced-stage carcinoma (HR: 3.08 (1.63.80), p = 0.001) and optimal debulking surgery (HR: 0.51 (0.32.80), p = 0.004) were critical prognostic factors within the multivariate evaluation. Cancer-related death with TLS gene mutation (HR: 33.76 (3.9589.00), p = 0.001), 1 DDR gene mutation (HR: 1.96 (1.20.20), p = 0.007), endometrioid carcinoma (HR: 0.12 (0.04.38), p 0.001), type II tumor (HR: 1.88 (1.19.96), p = 0.007), advanced-stage carcinoma (HR: 6.84 (3.284.25), p 0.001), high-grade tumor (HR: 17.97 (2.5029.29), p = 0.004) and optimal debulking surgery (HR: 0.26 (0.16.41), p 0.001) had been considerable in the univariate Cox regression model. Kind II tumor (HR: 0.35 (0.20.60), p 0.001), TLS gene mutation (HR: 9.57 (1.084.83), p = 0.042), advanced-stage carcinoma (HR: four.82 (two.091.09), p 0.001) and optimal debulking surgery (HR: 0.38 (0.22.64), p 0.001) had been critical prognostic things within the multivariate evaluation.Biomedicines 2021, 9,10 ofTable four. The correlation of DDR gene mutations with clinical parameters in the epithelial ovarian cancer individuals. Genes OSA Total HR Wild kind Mutation p value NHEJ Wild type Mutation p value MMR Wild kind Mutation p worth BER Wild sort Mutation p worth 160 93.02 12 six.98 65 94.20 four five.80 37 94.87 2 5.13 58 90.63 six 9.38 0.631 96 92.31 eight 7.69 64 94.12 four 5.88 0.649 65 94.20 4 five.80 95 92.23 eight 7.77 0.619 27 93.10 two six.90 133 93.01 10 six.99 0.985 66 94.29 four 5.71 94 92.16 8 7.84 0.59 91 94.79 5 five.21 69 90.79 7 9.21 0.306 161 93.60 11 6.40 67 97.10 2 two.90 33 84.62 6 15.38 61.